Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy
<p>Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by deficient estroge...
Saved in:
Main Authors: | Tze-Chen Hsieh (Author), Joseph M Wu (Author) |
---|---|
Format: | Book |
Published: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2020-07-18.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy for Tumor in the Brain: Insights From - and For - Other Tumor Sites
by: Lois A. Lampson
Published: (2018) -
Anthracycline-based combination chemotherapy (Doxorubicin and Dacarbazine) for the desmoid tumor in a neoadjuvant setting. Report of a case
by: Mahmood S, et al.
Published: (2021) -
Immunotherapy Myths, Reality, Ideas, Future
Published: (2017) -
Immunoregulatory Aspects of Immunotherapy
Published: (2018) -
Immunotherapy in Hepatocellular Carcinoma
Published: (2023)